



Press Release

Thursday, July 19, 2012



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR FLUOROURACIL INJECTION

July 19, 2012, Bangalore: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received 2 US FDA ANDA approvals for “Fluorouracil Injection USP, as under.

- 50 mg / mL, packaged in 10 mL and 20 mL single-dose vials
- 2.5 g/ 50 mL and 5 g / 100 mL Pharmacy bulk packages

Fluorouracil is amongst the products in the drug shortage list of US FDA. According to IMS data, the US market for generic Fluorouracil is approximately USD 14 Million.


Fluorouracil is part of the Oncology portfolio licensed to Pfizer for the US market and expected to be launched shortly

About Fluorouracil

Fluorouracil belongs to the class of chemotherapy drugs known as anti-metabolites. It interferes with cells making DNA and RNA, which stops the growth of cancer cells and is used to treat several types of cancer including colon, rectum, and head and neck cancers.

About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest sterile capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.



About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick
Mr. Ajay Singh : +91 80 6784 0813	Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Kannan N : +91 98450 54745 (Investors)	Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in

